相关实验视频

Updated: Jun 14, 2025

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

在微血管性心痛中使用齐博坦:随机化,安慰剂控制的交叉试验

Andrew Morrow¹, Robin Young², George R Abraham³

¹British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom (A.M., N.S., P.W.M., P.W., C.B.).

|September 1, 2024

概括

在患有微血管性心痛的患者中,齐博坦没有改善运动持续时间. 这种药物与不良事件的增加有关,并且在该患者群体中没有显示出有效性.

科学领域:

心脏病学
药理学
遗传学

背景情况:

微血管性心痛与内甲蛋白系统失调有关,影响心肌血流和生活质量.
SNP RS9349379的G等位基因增加了内甲素-1 (ET-1) 基因表达,可能会增加ET-1水平.
作为ET- A受体对抗剂的齐博的疗效和安全性尚未得到研究.

研究的目的:

评估齐博坦在治疗微血管性心痛中的疗效和安全性.
评估齐博坦对微血管性心痛患者的运动能力的影响.
研究RS9349379基因型与治疗反应之间的关系.

主要方法:

这是一项双盲,安慰剂对照的交叉试验,涉及微血管性心痛患者.
参与者被选定为RS9349379多态的50%G等位基因频率.
主要结果是跑步机运动持续时间的变化,次要结果评估了其他临床措施.

主要成果:

与安慰剂相比,齐博坦 (每天10毫克) 并没有显著改善运动持续时间 (差异为- 4. 26秒,P=0. 5871).
在二次疗效终点上没有观察到任何改善.
齐博坦导致不良事件发生率更高 (60. 2% vs 14. 4%) 和血压降低.

结论:

在患有微血管性心痛的患者中,使用齐博坦坦 (每天10毫克) 短期治疗是不有益的.
观察到的不良反应是常见的,与目标相关,这表明了潜在的安全问题.
可能需要进一步的研究来探索微血管性心痛的替代治疗策略.

关键词:

没有冠状动脉阻塞的胸痛内甲素受体对抗剂运动测试遗传学微血管性心痛药物治疗

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

相关概念视频

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...